Pierre Fabre is a French healthcare company active across pharmaceuticals and dermo-cosmetics, with global operations. The group combines R&D, manufacturing, and commercial activities.
Atara Biotherapeutics announced a Type A meeting with the FDA to discuss the Complete Response Letter for tabelecleucel's Biologics License Application, held by partner Pierre Fabre Pharmaceuticals.
The FDA issued a Complete Response Letter for Atara Biotherapeutics' Ebvallo application, reversing its prior acceptance of the ALLELE trial design. Partner Pierre Fabre Pharmaceuticals has requested a Type A meeting to address the agency's concerns.
